FUNDING CANCER - Assay Validation of High Quality Markers for Clinical Studies in Cancer (Multiple Mechanisms)
Sponsor: National Institutes of Health
Multiple Mechanisms:
PAR-23-313, UH2/UH3 Clinical Trial Not Allowed
PAR-23-314, UH3 Clinical Trials Not Allowed
Description: Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to accelerate the adoption and validation of molecular/cellular/imaging markers (referred to as "markers" or "biomarkers") and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. This NOFO will also support the validation of pharmacodynamic markers and markers of toxicity. Applicants to this NOFO must have an assay(s) whose performance has been analytically validated in specimens similar to those for the intended clinical use of the marker(s) and assay(s). As chemotherapies and/or radiation therapies are increasingly combined with immunotherapies to enhance the durability of anti-cancer responses, assays for measuring multiple markers, including immune markers, can be developed and validated simultaneously.
- Next Application Deadline: October 8, 2024
-
Future Deadlines:
-
February 14, 2025
- June 11, 2025
- October 15, 2025
- February 13, 2026
- June 10, 2026
- October 14, 2026
To view all current UVACCC funding opportunities, please click here.
For all open cancer-related funding opportunities, please click here.